IMMU-110, being evaluated in a Phase I/II study, is comprised of doxorubicin (DOX) linked to the humanized anti-CD74 monoclonal antibody via an acid-liable hydrazone, which showed high activity against MM, and appeared to be safe in a monkey model of MM cells [61,62]. This evidence concerns the gene CD74 and Miyoshi myopathy.